Burosumab

布罗索尤单抗

Report date: 2026/01/07 16:32:38
First In Class

Base Information

Drug NameBurosumab
Drug Alias Name布洛舒单抗BurosumabumBurosumab-twzaAnti-FGF 23 monoclonal antibodyAnti-fibroblast growth factor 23 monoclonal antibody +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionFibroblast growth factor 23 antagonists
TargetsFibroblast growth factor 23
Therapy Area/IndicationsHypophosphatemiaGenetic Diseases, X-LinkedHypophosphatemia, Familial +[7] 
Global Approved IndicationsGenetic Diseases, X-LinkedHypophosphatemia, FamilialFamilial Hypophosphatemic Rickets +[4] 
Approved Indications in ChinaGenetic Diseases, X-Linked
Original Approved Country/TerritoryEU
Original Approved Date2018/02/19
Country/TerritoryCanadaUnited StatesSweden +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKyowa Kirin IncKyowa Kirin Co LtdKyowa Kirin +[7] 
Inactive CompaniesKyowa Hakko Kirin Pharma IncUltragenyx Pharmaceutical Inc
Active IndicationsHypophosphatemiaGenetic Diseases, X-LinkedHypophosphatemia, Familial +[6] 
Inactive IndicationsNevus, Sebaceous of Jadassohn

Other Information

ATC CodeM05BX05
Related LinksWikipedia